Nov 04, 2009 (Hugin via COMTEX) -- Oslo, Norway, 04 November 2009 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, will announce its third quarter 2009 results on Friday, 13 November 2009. A presentation to investors, analysts and the press will take place in Oslo at 08:15 CET. Algeta's President and CEO Andrew Kay, CTO Thomas Ramdahl and CFO Oystein Soug will present. An international conference call will take place at 14:30 CET (details below). Andrew Kay, Thomas Ramdahl and Oystein Soug will participate.

The presentation will take place at 08:15 CET at:

Hotel Continental Stortingsgaten 24/26 0117 Oslo Norway.

Breakfast will be served from 07:45 CET.

To participate in the conference call, please dial the appropriate number below five minutes prior to the call:

800 80 119 (in Norway) +47 23 00 04 00 (from abroad).

The results report and the presentation will be made available on www.algeta.com in the Investors section from 08:00 CET.

To access the replay, please dial +47 67 89 40 91. Enter account no. 1428 followed by #, then press 1, conference no. 428 followed by #. Press 1 to play. A replay version of the conference call will also be available at www.algeta.com.

###

For further information, please contact

Andrew Kay, CEO Oystein Soug, CFO +47 23 00 67 42 / +47 484 01 360 (mob) +47 23 00 79 84 / +47 906 56 525 (mob) post@algeta.com

Dr Mark Swallow / David Dible +44 (0) 207 638 9571 / Helena Galilee mark.swallow@citigatedr.co.uk Citigate Dewe Rogerson

About Algeta Algeta ASA is a cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing a new generation of targeted cancer therapeutics (alpha-pharmaceuticals) that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.

Algeta's lead alpha-pharmaceutical candidate, Alpharadin (based on radium-223), has blockbuster potential for treating bone metastases arising from multiple major cancer types, owing to its bone-targeting nature, potent efficacy (therapeutic and palliative) and benign, placebo-like safety profile. Development of Alpharadin is most advanced targeting bone metastases resulting from hormone-refractory prostate cancer (HRPC), and it entered an international phase III clinical trial (ALSYMPCA) in mid-2008 based on compelling clinical results from a comprehensive phase II program.

Algeta's strategy is to launch Alpharadin as a first or second line treatment for cancer patients with bone metastases either alone or in combination with current standard of care therapies, thereby maximizing its commercial potential.

Algeta is also developing other technologies for delivering alpha-pharmaceuticals. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.

###

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

SOURCE: Algeta ASA

Copyright (c) 2009, HUGIN AS. All rights reserved.

KEYWORD: Norway SUBJECT CODE: Corporate events

Manufacture of pharmaceuticals, medicinal chemicals and botanical products ORGANIZATION: Algeta ASA